Join
Live feed
·
PRReleasevia Quantisnow
Aldeyra Therapeutics Inc. logo

Aldeyra Therapeutics Achieves Primary Endpoint in Part 1 of Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy

ByQuantisnow·Wall Street's wire, on your screen.
ALDX· Aldeyra Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ALDX (Aldeyra Therapeutics Inc.) and more on Quantisnow.